Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)
Latest Information Update: 30 Sep 2022
At a glance
- Drugs Dihydrotetrabenazine (Primary)
- Indications Drug-induced dyskinesia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Adeptio Pharmaceuticals
Most Recent Events
- 30 Sep 2022 New trial record